Pemgarda has a standing emergency use authorization as a prophylaxis for immunocompromised patients, but FDA’s stringent ...

FDA denies Invivyd's EUA expansion for Pemgarda in Covid treatment while BioCryst reports positive Orladeyo data. AN2 changes endpoint, OS Therapies seeks partners & Eyenovia restructures.

H.C. Wainwright maintains a Buy rating on Invivyd (IVVD) with a $10 price target after the FDA rejected its submission to expand Pemgarda’s ...

Invivyd's bid to expand Pemgarda's EUA for COVID-19 treatment was denied by the FDA. The company will share new data on ...

Monday said that its request to expand the existing emergency use authorization of PEMGARDA (pemivibart) to include treatment of mild-to-moderate COVID-19 for immunocompromised persons who have no ...

The commercial-stage biopharmaceutical company said its request to expand the existing emergency use authorization of the drug, also called pemivibart, to treat mild-to-moderate Covid-19 in more ...

Invivyd (IVVD) announced that Invivyd’s request to expand the existing emergency use authorization for pre-exposure prophylaxis of COVID-19 EUA ...

We recently compiled a list of the 10 Micro and Small-Cap Firms Drive Year-to-Date Gains. In this article, we are going to ...

New cases are still being recorded, and the impact of long COVID has yet to be fully determined. Invivyd announced a ...

Biotechnology is a high-risk, high-reward landscape where innovation determines success. Yet, occasionally, a small player flips the script. Invivyd (IVVD), a biomedical firm specializing in ...

Invivyd, Inc. focuses on developing antibody-based treatments for infectious diseases, primarily COVID-19, with promising projects like PEMGARDA and VYD2311. Strong Q4 performance with a 48% ...

The primary target is COVID-19. The stock has surged significantly so far in 2025 due to Q4 2024 net product revenue for PEMGARDA surging 48% quarter-over-quarter to $13.8 million. This is on top ...